The anti-PD-1 monoclonal antibody drug has been co-developed by Akeso and Sino Biopharmaceutical
Akeso announced that the anti-PD-1 monoclonal antibody drug Penpulimab monoclonal antibody injection co-developed by the company with Sino Biopharmaceutical has obtained marketing approval by the National Medical Products Administration (the NMPA) of China, for treatment of patients with relapsed or refractory (r/r) classic Hodgkin’s lymphoma (cHL) after at least second-line systemic chemotherapy treatment.
The approval of Penpulimab by the NMPA is based on a multicentre, single-arm, open-label pivotal clinical trial. Patients enrolled were r/r cHL patients who had failed at least second-line systemic chemotherapy and were administered 200 mg Penpulimab monoclonal antibody by intravenous injection once every two weeks until progress is made or reached unacceptable toxicity. The key research endpoint was the objective response rate (ORR) evaluated by the independent radiology review committee (IRRC) concerning the Lugano 2014 lymphoma efficacy rating criteria.
Penpulimab is currently the only new PD-1 monoclonal antibody that applies IgG1 subtype and is modified by the Fc segment, which has a lower antigen-binding dissociation rate and a unique binding epitope as demonstrated by analysis on the crystal structure. These features allow Penpulimab to effectively and continuously block PD-1/PD-L1 binding, thus differentiates it from other PD-1 products on the market, and may allow Penpulimab to more effectively enhance immunotherapeutic efficacy and reduce immune-related adverse reactions, as demonstrated by improved safety profile in clinical data.
Penpulimab is Akeso’s first innovative antibody-protein drug that has been granted marking approval with major research studies covering major oncology diseases such as liver cancer, gastric cancer, lung cancer, Hodgkin’s lymphoma and nasopharyngeal carcinoma. In addition to the said approval for the treatment of cHL, Penpulimab has submitted 2 NDAs in China and 1 biologics license application (“BLA”) in the U.S.:
In August 2021, the NDA of Penpulimab for third-line treatment of metastatic nasopharyngeal carcinoma was submitted and was accepted by the NMPA.
In July 2021, NDA of Penpulimab for combined chemotherapy for first-line treatment of locally advanced or metastatic squamous non-small-cell lung cancer was submitted and was accepted by the NMPA.
In May 2021, Penpulimab for third-line treatment of metastatic nasopharyngeal carcinoma has been submitted to the Food and Drug Administration of the United States (FDA) for a BLA through the Real-Time Oncology Review (RTOR) programme.
